Home » Topics » Disease categories and therapies » Musculoskeletal

Musculoskeletal
RSS

Preliminary data presented from phase I/II ASPIRO study of AT-132

Oct. 9, 2019

XBiotech initiates phase II study of bermekimab in systemic sclerosis

Oct. 3, 2019

New registrational study evaluates miransertib in Proteus syndrome and PROS

Oct. 2, 2019

TLC initiates phase III pivotal EXCELLENCE study of TLC-599

Oct. 2, 2019

Development and characterization of IRAK-4 inhibitors

Sep. 30, 2019

Inflazome begins first-in-human study of IZD-334 for CAPS

Sep. 27, 2019

Positive topline results presented from phase II STAR study of tolperisone

Sep. 25, 2019

Phase III PREVENT trial of Cosentyx in nr-axSpA meets 16-week primary endpoint

Sep. 17, 2019

DSMC recommends continuation of U.S. study of IDCT for degenerative disc disease

Sep. 17, 2019

BoNTANA Therapies describes nucleic acids encoding botulinum neurotoxins

Sep. 13, 2019

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 26, 2026.
Brain-computer interfaces are here but long road ahead
BioWorld
The field of BCI is continually evolving; as such, companies are increasingly highlighting the potential of their technologies to transform care. For advanced...
Next wave of BCI firms builds on pioneers to tackle challenges
BioWorld
With the pace of neurotechnology development accelerating, a wave of brain-computer interface (BCI) companies is emerging on the heels of the pioneers. In the...
Boehringer Ingelheim identifies new mGlu3 receptor agonists
BioWorld Science
Boehringer Ingelheim Pharma GmbH & Co. KG and Vanderbilt University have discovered new dihydrobenzoxazine compounds acting as metabotropic glutamate mGlu3...
ENCALS 2026: From genetics to advancing strategies against ALS
BioWorld Science
Amyotrophic lateral sclerosis (ALS)-associated genes provide direct therapeutic targets and reveal pathways that can be used to develop treatments that counteract...